MANILA, Philippines — The Philippine government will consider reported cases of “rare” blood clotting among people vaccinated with Janssen Pharmaceuticals’ COVID-19 jab in its deliberations on the drug maker’s emergency use authorization (EUA) application.
According to Department of Health (DOH) Undersecretary Maria Rosario Vergeire, the Belgium-based pharma owned by the US company Johnson & Johnson (J&J) has to submit to the country’s Food and Drug Administration (FDA) all studies related to its clinical trials of the vaccine.
This comes after the United States and South Africa temporarily suspended the administration of the Janssen COVID-19 jab amid reported blood c…
Keep on reading: DOH says gov’t to consider reports of ‘rare’ blood clot on J&J jab’s EUA